September 7, 2016 8:27am

For Development of Off-the-Shelf T-Cell Immunotherapies as collaboration uses engineered Pluripotent Cell Lines to renewably generate T-Cell Product candidates - BUY

 

 

FATE partnered with Memorial Sloan Kettering Cancer Center for the development of off-the-shelf T-cell product candidates using engineered pluripotent cell lines.

  • Research and development activities under the multi-year collaboration will be led by Michel Sadelain, M.D., Ph.D.Director of the Center for Cell Engineering and the Stephen and Barbara Friedman Chair at Memorial Sloan Kettering Cancer Center.

 

 

The Bottom Line:  this partnership brings together Memorial Sloan Kettering’s manufacture and delivery of cell-based immunotherapies, and FATE’s established expertise in pluripotent cell generation, engineering and differentiation.

  • Engineering therapeutic attributes into pluripotent cell lines, such as antigen specificity, lack of alloreactivity, enhanced persistence and histocompatibility is a breakthrough approach to renewably generate potent T-cell immunotherapies.

In connection with the partnership, FATE has exclusively licensed from Memorial Sloan Kettering foundational intellectual property covering induced pluripotent cell-derived immune cells, including T cells and NK cells derived from pluripotent cells engineered with chimeric antigen receptors, for human therapeutic use. Additionally, FATE maintains an option to exclusively license intellectual property arising from all research and development activities under the collaboration.

FATE closed at $2.43 which was UP +$0.05 - BUY

 

Cellular immunotherapies are poised to transform the treatment of cancer and immunological conditions. However, cellular immunotherapies currently undergoing clinical investigation are patient-specific and their delivery requires the extraction, engineering, expansion and re-introduction of each individual patient’s T cells. This multi-step manufacturing process is logistically challenging and complex, and significant hurdles remain to ensure that patient-specific T-cell immunotherapies can be efficiently and consistently manufactured, and safely and reliably delivered, at the scale necessary to support broad patient access and wide-spread commercialization.